Pfizer Ltd. — Regulatory Filings 2019

Jun 26, 2019

The Capital, 1802 / 1901 , Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai ltOO 051 . Tel: +91 22 6693 2000 Fax : +91 22 265lt 027lt

June 26, 2019

The Corporate Relationship Dept. BSE Limited l 5 t Floor, P.J.Towers Dalal Street, Fort Mumbai - 400 001 Scrip Code: 500680

The Manager, Listing Dept. The National Stock Exchange of India Ltd. Exchange'Plaza, 5th Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Sandra (E) Mumbai - 400 051 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

·- Pursuant to Regulation 23(9) of the Listing Regulations; please find enclosed, disclosure of related party transactions on a consol'idated basis, in the fmmat specified in the accounting standards for the year ended March 31, 2019.

The said disclosure is also available on the website of the Company i.e., www.pfizerindia .com

Please take the above on record.

Thanking you,

Yours truly,

For i

Pra l~air

Company Secretary

CIN: L2lt231MH1950PLC008311 [8J contactus.india@pfizer.com

~l www_pfizerindia.com

DISCLOSlJRJi; OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2019

Currency: ~ in crore

Related party transactions

I. Names of related parties and description of relationships

A. Parties where control exists:

Ultimate holding company: Pfizer Inc., USA

B. Companies collectively exercising significant influence: Pfizer East India B. V., Netherlands Wyeth LLC, USA Wyeth Holdings Corporation, USA John Wyeth & Brother Limited, UK Warner - Lambert Company, LLC, USA Parke - Davis & Company, LLC, USA Pharmacia Corporation, USA [Collectively holding 63.92% of the aggregate of equity share capital of the Company]

C. Fellow subsidiaries with whom transactions have taken place during the year

Pfizer Products India Private Limited, India Pfizer Innovative Supply Point Intl BVBA, Belgium Pfizer Service Company BVBA, Belgium Pfizer Worldwide Services, Ireland

D. Key managerial personnel

Mr. S. Sridhar - Managing Director Mr. Mil ind Patil - Chief Financial Officer (w.e. f 16 August 2018) Wholetirne Director (w.e.f 14 November 2018)

Mr. Vivek Dhariwal - Wholetime Director Dr. Anurita Majumclar - Wholetime Director (upto 8 March 2019)

Mr. RA Shah - Independent Director

Mr. Pradip Shah - Independent Director

Mr. Uday Khanna - Independent Director

Mr. Sunil Lalbhai - Independent Director

Ms.Meena Ganesh - Independent Director ( w.e.f 8 March 2019 ) Mr. Ravi Prakash Bhagavathula - Chief Financial Officer ( upto 31 March 2018) Wholetirne Director (up1o 28 February 2018)

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR Tl-IE FINANCIAL VEAR ENDED MARCl-131, 2019

Currency: ~ in crore

Related party transactions (Cfmtinued)

JI. Transactions during the year and balances outstanding as at the year end with the related parties are as follows:

		31 March 201?			::!I March 2018
	No. Nature of transactions	Ultimateholdingcompany	Companiesexercisingsignificantinfluence	Fellowsubsidiaries	Total	Ultimateholdingcompany	Companiesexercisingsignificantinfluence	Fellowsubsidiaries	Total
	Service income	0.37		50.56	50.93	1.27		54.02	55.29
	Ri;covery of expenses			0.36	0.36			U4	U4
	Purchase of stock-in-trade			3?6.42	3?6.42			273.63	273.63
	Purchase ofrnw I bulk materials			49.98	49.98			59.83	59.8}
	Reimbursement of expenses	0.27			0.27	0.88		3.33	4.21
	Dividend in respect of the year ended 31 March 2018 I2017		58.49		58.49		58.4')		58.4')
7								2.97	2.97
		31 March 2019				3 I March 20 I 8
	No. Nature of transactions	llltimateholdingcompany	Companiesexercisingsignificantinfluence	Fellowsubsidiaries	Total	Ultimateholdingcompany	Companiesexercisingsignificantinfluence	Fellowsubsidiaries	Total
	Outstanding as at the year end - Due from	0.33	0.06	19.21	19.60	0.20		14.83	15.03
	Outstanding as at the year end - Due. to	10.52	7.84	254.97	273.33	9.76	7.76	290. 15	307.67

Key managerial personnel

--------Key managerial personnel
--·----·------------·--·----------.No. Nature of transactions	Vear ended	Year ended
	31March2019	3 I March 2018
Remuneration to key management personnel ·~	10.39	10.06

''' Excl udes amounts payable to key management personnel towards gratuity, compensated absences and provident fund.

Details of material transactions during the year:

		Year ended	Year ended
		31 March 201?	3 I March 2018
a)	Service income		------~---1
	Pfizer Products India Private Limited	23.22	19.79
	Pfizer Worldwide Services	27.34	34.23
h)	Service charge
	Pfizer Products India Private Limited		2.97
c)	Recovery of expenses
	Pfizer Products India Private Limited	0.34	1.31
d)	Purchase of stock in trade
	Pfizer Innovative Supply Point Intl BVBA, Belgium	258.18	242.60
	Pfizer Service Company BVBA, Belgium	131.?3	27.4')
e)	Purchase of raw/ hulk materials
	Pfizer Service Company BVBA, Belgium	46.87	55.49
f)	Reimbursement of expenses
	Pfizer Investment Co., Ltd		3.20
	Pfizer Inc., USA	0.27	0.88
g)	Dividend paid
	Pfizer East India B. V.	36.37	36.37
	Wyeth LLC, USA	11.24	I 1.24
h)	l{emuneration to key management personnel
	S. Sridlm	3.55
	Milind Patil	1.59
	Vivek Dhariwal	2.53	1.92
	Dr. Anurita Majumdar	1.96	1.74
	Ravi Prnkash Bhagavathula		2.30

DISCLOSIJRE OF RELATED PARTY TRANSACTIONS FOR TI-IE FINANCIAL VEAR ENDED MARCI-131, 2019

Currency: ~ in crore

Related party transactions (Continued)

		As on	As on31 March2019 31 March2018
i)	Outstanding as at the year end due from
	Pfizer Worldwide Services	5.47	9.49
	Pfizer Products India Private Limited, India	13.74	5.34
.D	Outstanding as at the year end due to
	Pfizer Innovative Supply Point Intl BVBA, Belgium	62.49	145.27
	Pfizer Service Company BVBA, Belgium	83.97	32.65
	Pfizer Export Company, Ireland	84.70	57.4 I